ANDA 40641, held by Bedford Laboratories. Methylprednisolone Sodium Succinate.
As of Nov 18, 2026, ANDA 40641 (Methylprednisolone Sodium Succinate), held by Bedford Laboratories, was first approved by FDA on Feb 21, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 21, 2007 | Original application | Approved | None posted |
| Methylprednisolone Sodium SuccinateEQ 125MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Methylprednisolone Sodium SuccinateEQ 500MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
| Methylprednisolone Sodium SuccinateEQ 1GM BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters